

Jonas S Jutzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3342345/publications.pdf>

Version: 2024-02-01

16
papers

495
citations

1162889

8
h-index

1281743

11
g-index

16
all docs

16
docs citations

16
times ranked

917
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
2	LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. <i>HemaSphere</i> , 2018, 2, e54.	1.2	74
3	MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. <i>Journal of Experimental Medicine</i> , 2013, 210, 1003-1019.	4.2	69
4	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. <i>Journal of Experimental Medicine</i> , 2012, 209, 35-50.	4.2	67
5	BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. <i>Cell Death and Disease</i> , 2020, 11, 8.	2.7	37
6	Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. <i>Blood</i> , 2018, 131, 2065-2073.	0.6	36
7	Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. <i>Blood</i> , 2019, 133, 1766-1777.	0.6	23
8	The Hen or the Egg: Inflammatory Aspects of Murine MPN Models. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	9
9	Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. <i>Leukemia</i> , 2020, 34, 721-734.	3.3	6
10	Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice. <i>PLoS ONE</i> , 2020, 15, e0228362.	1.1	4
11	The Cross Marks the Spot: The Emerging Role of JmjC Domain-Containing Proteins in Myeloid Malignancies. <i>Biomolecules</i> , 2021, 11, 1911.	1.8	4
12	Mutations In Transcription Factor NF-E2 Confer Resistance To Interferon Treatment In MPN Patients. <i>Blood</i> , 2013, 122, 4096-4096.	0.6	0
13	Title is missing!. , 2020, 15, e0228362.		0
14	Title is missing!. , 2020, 15, e0228362.		0
15	Title is missing!. , 2020, 15, e0228362.		0
16	Title is missing!. , 2020, 15, e0228362.		0